| Literature DB >> 27479497 |
Karen M Mann1,2, Justin Y Newberg1, Michael A Black3, Devin J Jones1, Felipe Amaya-Manzanares1, Liliana Guzman-Rojas1, Takahiro Kodama1, Jerrold M Ward2, Alistair G Rust4, Louise van der Weyden4, Christopher Chin Kuan Yew2, Jill L Waters5, Marco L Leung5, Keith Rogers2, Susan M Rogers2, Leslie A McNoe3, Luxmanan Selvanesan3, Nicholas Navin5, Nancy A Jenkins1,2, Neal G Copeland1,2, Michael B Mann1,2.
Abstract
A central challenge in oncology is how to kill tumors containing heterogeneous cell populations defined by different combinations of mutated genes. Identifying these mutated genes and understanding how they cooperate requires single-cell analysis, but current single-cell analytic methods, such as PCR-based strategies or whole-exome sequencing, are biased, lack sequencing depth or are cost prohibitive. Transposon-based mutagenesis allows the identification of early cancer drivers, but current sequencing methods have limitations that prevent single-cell analysis. We report a liquid-phase, capture-based sequencing and bioinformatics pipeline, Sleeping Beauty (SB) capture hybridization sequencing (SBCapSeq), that facilitates sequencing of transposon insertion sites from single tumor cells in a SB mouse model of myeloid leukemia (ML). SBCapSeq analysis of just 26 cells from one tumor revealed the tumor's major clonal subpopulations, enabled detection of clonal insertion events not detected by other sequencing methods and led to the identification of dominant subclones, each containing a unique pair of interacting gene drivers along with three to six cooperating cancer genes with SB-driven expression changes.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27479497 PMCID: PMC6124494 DOI: 10.1038/nbt.3637
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908